2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2049

Expression and Function of a Novel Citrullinated Form of Interleukin 6 in Rheumatoid Arthritis
Abstract Number: 20

Expression and Functions of the Transcription Factors Ikaros and Aiolos in Sjogren’s Syndrome and Systemic Lupus Erythematosus
Abstract Number: 1586

Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients
Abstract Number: 95

Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis
Abstract Number: 1107

Expression Quantitative Trait Loci -eQTL- Analysis in Systemic Sclerosis
Abstract Number: 2029

Extended Phenotypic Immunome Characterization (EPIC): A Web-Based Immune Reference Atlas
Abstract Number: 2753

Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Abstract Number: 1418

External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
Abstract Number: 1593

Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center
Abstract Number: 1101

Extracellular Vesicle-Mediated Delivery of EBV SMALL RNA (EBER1) Activates LUPUS Nephritis Related Antiviral Immunity in Tubular Epithelial CELLS VIA TLR3
Abstract Number: 1335

Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
Abstract Number: 2366

Facilitating Shared Decision Making in Psoriatic Arthritis: Factors Influencing Patient Preference for Treatment Mode of Administration
Abstract Number: 298

Factors Affecting Inpatient Mortality in Hospitalizations for Sepsis with Underlying Systemic Lupus Erythematosus: Data from the National Inpatient Sample 2010-2014
Abstract Number: 2285

Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Abstract Number: 1801

Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].